Class information for:
Level 1: INTERLEUKIN 2//LYMPHOKINE ACTIVATED KILLER CELLS//RECOMBINANT INTERLEUKIN 2

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1306 2627 33.4 76%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1213 8727 INTERLEUKIN 2//GRANZYME B//PERFORIN

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INTERLEUKIN 2 Author keyword 66 13% 18% 464
2 LYMPHOKINE ACTIVATED KILLER CELLS Author keyword 16 28% 2% 49
3 RECOMBINANT INTERLEUKIN 2 Author keyword 11 37% 1% 23
4 JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS Journal 8 13% 2% 62
5 LAK CELLS Author keyword 7 22% 1% 29
6 RUPPERT Address 6 100% 0% 4
7 LYMPHOKINE ACTIVATED KILLER CELL Author keyword 4 20% 1% 17
8 LYMPHOKINE ACTIVATED KILLER ACTIVITY Author keyword 4 41% 0% 7
9 ADVANCED RENAL CANCER Author keyword 3 57% 0% 4
10 IL 2 LIPOSOMES Author keyword 3 100% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 INTERLEUKIN 2 66 13% 18% 464 Search INTERLEUKIN+2 Search INTERLEUKIN+2
2 LYMPHOKINE ACTIVATED KILLER CELLS 16 28% 2% 49 Search LYMPHOKINE+ACTIVATED+KILLER+CELLS Search LYMPHOKINE+ACTIVATED+KILLER+CELLS
3 RECOMBINANT INTERLEUKIN 2 11 37% 1% 23 Search RECOMBINANT+INTERLEUKIN+2 Search RECOMBINANT+INTERLEUKIN+2
4 LAK CELLS 7 22% 1% 29 Search LAK+CELLS Search LAK+CELLS
5 LYMPHOKINE ACTIVATED KILLER CELL 4 20% 1% 17 Search LYMPHOKINE+ACTIVATED+KILLER+CELL Search LYMPHOKINE+ACTIVATED+KILLER+CELL
6 LYMPHOKINE ACTIVATED KILLER ACTIVITY 4 41% 0% 7 Search LYMPHOKINE+ACTIVATED+KILLER+ACTIVITY Search LYMPHOKINE+ACTIVATED+KILLER+ACTIVITY
7 ADVANCED RENAL CANCER 3 57% 0% 4 Search ADVANCED+RENAL+CANCER Search ADVANCED+RENAL+CANCER
8 IL 2 LIPOSOMES 3 100% 0% 3 Search IL+2+LIPOSOMES Search IL+2+LIPOSOMES
9 VASCULAR LEAK SYNDROME 3 31% 0% 8 Search VASCULAR+LEAK+SYNDROME Search VASCULAR+LEAK+SYNDROME
10 LOCOREGIONAL IMMUNOTHERAPY 3 50% 0% 4 Search LOCOREGIONAL+IMMUNOTHERAPY Search LOCOREGIONAL+IMMUNOTHERAPY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ACTIVATED KILLER CELLS 167 28% 19% 512
2 RECOMBINANT INTERLEUKIN 2 157 26% 20% 523
3 CONTINUOUS INFUSION INTERLEUKIN 2 69 66% 2% 65
4 HIGH DOSE INTERLEUKIN 2 65 30% 7% 185
5 RECOMBINANT HUMAN INTERLEUKIN 2 62 44% 4% 108
6 REPETITIVE WEEKLY CYCLES 61 78% 2% 40
7 ADVANCED CANCER 37 15% 9% 226
8 LAK CELLS 29 31% 3% 80
9 PURIFIED HUMAN INTERLEUKIN 2 25 51% 1% 35
10 ESTABLISHED PULMONARY METASTASES 25 36% 2% 56

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS 8 13% 2% 62
2 CANCER BIOTHERAPY 3 17% 1% 16

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
INTERLEUKIN-2 TOXICITY 1991 352 69 75%
Natural history and therapy of metastatic renal cell carcinoma - The role of interleukin-2 1997 191 184 67%
CHEMOTHERAPY FOR ADVANCED RENAL-CELL CARCINOMA - 1983-1993 1995 277 122 41%
Application of IL-2 and other cytokines in renal cancer 2004 54 99 62%
IMMUNOTHERAPY FOR METASTATIC RENAL-CELL CARCINOMA 1993 127 80 90%
INTERLEUKIN-2 - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN PATIENTS WITH CANCER 1993 183 459 58%
Chemotherapy for renal cell carcinoma 2000 124 143 47%
Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy 2009 19 166 39%
Guidelines for the safe administration of high-dose interleukin-2 2001 61 13 54%
Vascular leak syndrome: a side effect of immunotherapy 1997 129 149 38%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 RUPPERT 6 100% 0.2% 4
2 SECT MELANOMA RENAL CANC IMMUNOTHER Y 2 50% 0.1% 3
3 UNITE ONCOL RADIOTHER IE 1 100% 0.1% 2
4 PRECLIN ONCOL DEV THER EUT 1 33% 0.1% 2
5 OPERAT UNIT UROL 1 21% 0.1% 3
6 AMTSSYGEHUSET HERLEV 1 50% 0.0% 1
7 BIOPHYSIOL BIOPHYS 1 50% 0.0% 1
8 CANC EXPT THER EUT PROGRAM 1 50% 0.0% 1
9 CATALA ONCOL HEMATOL 1 50% 0.0% 1
10 CHAIR MED EXPTL ONCOL 1 50% 0.0% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000246856 MHC NONRESTRICTED CYTOTOXICITY//HISTAMINE DIHYDROCHLORIDE//BOWYER ONCOL
2 0.0000216893 TUMOR INFILTRATING LYMPHOCYTES//ADOPTIVE IMMUNOTHERAPY//AUTOLYMPHOCYTE THERAPY
3 0.0000159409 PIT CELLS//ACTIVATED NATURAL KILLER CELLS//A NK CELLS
4 0.0000135501 INTIMA TO MEDIA RATIO//EPIDEMIOL HLTH BEHAV SOC//BIOL DOSE SECT
5 0.0000090815 GIRENTUXIMAB//G250//MONOCLONAL ANTIBODY CG250
6 0.0000089143 INHIBITORY MODULATION//TAC ANTIGEN//PROGRAMA NEUROIMUNOL NEUROBIOL
7 0.0000087182 BIOCHEMOTHERAPY//METASTATIC MELANOMA//DACARBAZINE
8 0.0000085580 MHC AF//IMMUNODIAG//CARBOHYDRATE COMPONENT
9 0.0000084738 ADV CELL MOL THER Y//SHUNDE PEOPLES HOSP//TUMOR VACCINE
10 0.0000084106 INTERLEUKIN 2 RECEPTOR//IL 2 RECEPTOR//IL 2 RECEPTOR GAMMA CHAIN